特应性皮炎
安慰剂
双盲
医学
皮肤病科
双盲研究
内科学
替代医学
病理
作者
Melinda Gooderham,Emma Guttman‐Yassky,Ken Igawa,Kenji Kabashima,Ehsanollah Esfandiari,Angela J. Rylands,Angela Williams,Annabel Nixon,Jennifer E. Dent,Eric L. Simpson
标识
DOI:10.1007/s13555-024-01303-z
摘要
In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to assess the impact of rocatinlimab on patient-reported outcomes (PROs).
科研通智能强力驱动
Strongly Powered by AbleSci AI